Nurix Therapeutics (NRIX) Operating Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has 6 years of Operating Leases data on file, last reported at $55.5 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $55.5 million, up 177.49% year-over-year; the trailing twelve-month figure through Feb 2026 was $55.5 million (up 177.49% YoY), and the FY2025 annual result was $52.9 million, up 160.76% from the prior year.
• Operating Leases advanced to $55.5 million in Q1 2026 per NRIX's latest filing, from $52.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $55.5 million in Q1 2026 and troughed at $2.6 million in Q3 2023.
• A 5-year average of $19.9 million and a median of $20.0 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases surged 679.33% in 2024, then plunged 72.23% in 2025.
• A 5-year view of Operating Leases shows it stood at $6.4 million in 2022, then jumped by 259.42% to $23.1 million in 2023, then slipped by 12.26% to $20.3 million in 2024, then jumped by 160.76% to $52.9 million in 2025, then gained by 4.81% to $55.5 million in 2026.
• Business Quant data shows NRIX's Operating Leases at $55.5 million in Q1 2026, $52.9 million in Q4 2025, and $52.7 million in Q3 2025.